Loading the player...
Closed Captioning / Subtitles Available
Information
The Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease, Nonalcoholic Steato Hepatitis, Cirrhosis, & Hepatoma
Copyright :
Nonalcoholic Fatty Liver Disease (NAFLD) affects 24% of the US population and only 5% are aware of their disease. That’s staggering when you consider how NAFLD can progress to Nonalcoholic Steato Hepatitis, Cirrhosis, and Hepatoma.
How can we diagnose and follow these patients in a primary care setting? What treatments are available? What is the data on these treatments?
Please join Peter Buch, MD as he discusses the important role that you will play in treating a tsunami of future liver disease due to NAFLD. This will be done in a practical, case based, very interactive and fun format. You’ll conclude with practical, useful clinical tools necessary to help you NAFLD patients.
Peter Buch, MD, AGAF, FACP
Peter Buch, MD, AGAF, FACP, is a double board-certified clinical gastroenterologist, leading a team that treats all GI conditions. Dr. Buch sits on editorial boards for numerous professional journals and is a highly sought-after international presenter.
Dr. Buch has a passion for teaching. His style is case-based, practical, very interactive and evidence supported. Dr. Buch’s expertise has been shared with experienced clinicians and advanced-level students. He teaches at the University of Connecticut School of Medicine, the University of New England College of Osteopathic Medicine, the Frank H Netter School of Medicine/Quinnipiac University and the University of Connecticut APRN School.
Speaker Disclosures:
Financial: Dr. Peter S. Buch has employment relationships with the University of Connecticut School of Medicine, the University of New England College of Osteopathic Medicine, and the Frank H Netter, MD School of Medicine. He receives a speaking honorarium and recording royalties from PESI, Inc. He has no relevant financial relationships with ineligible organizations.
Non-financial: Dr. Peter S. Buch serves on the FDA and Patient Care Committees at the American College of Gastroenterology. He serves as an editor of peer-reviewed journals. He is a member of the International Association of Medical Science Educators, the AGA Academy of Educators, the American Gastroenterological Association (AGAF), the American College of Physicians (FACP), the Hartford County Medical Association, the American College of Gastroenterology (FACG), and the Connecticut State Medical Society.
Content Disclosure:
Dr. Buch references the use of antidepressants for Irritable Bowel Syndrome, and the controversial use of Fibrotest to evaluate patients with fatty liver disease who may have fibrosis of the liver. Dr. Buch indicates he wishes to present a fair and balanced approach to practitioners regarding such practices.
